May 31 |
Psychedelic stocks mixed as FDA comments on MDMA therapy (update)
|
May 23 |
Psychedelics Closer To Commercialization; Compass Far And Away The Leader
|
May 21 |
These 2 Catalysts Could Soon Send Compass Pathways Stock Soaring
|
May 13 |
COMPASS Pathways plc (NASDAQ:CMPS) Q1 2024 Earnings Call Transcript
|
May 11 |
COMPASS Pathways plc (CMPS) Q1 2024 Earnings Call Transcript
|
May 9 |
Compass Pathways Plc (CMPS) Q1 2024 Earnings Call Transcript
|
May 8 |
COMPASS Pathways ADS GAAP EPS of -$0.55 misses by $0.07
|
May 8 |
Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights
|
May 8 |
Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder
|
May 3 |
Compass Pathways to announce first quarter financial results on May 8, 2024
|